Citations

Clear

3942 citation(s) found for "To, Van".

Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach
Baker, Angela , Braggio, Esteban , Jacobus, Susanna , Jung, Sungwon , Therneau, Terry M. , Dispenzieri, Angela , Wier, Scott A. Van, Ahmann, Gregory , Levy, Joan, Perkins, Louise M. , Kim, Seungchan , Henderson, Kimberly J., Vesole, David H., Rajkumar, S. Vincent , Jelinek, Diane F., Carpten, John D. , Fonseca, Rafaël , Larson, Dirk R. , Rajkumar, S Vincent , Dispenzieri, Angela , Braggio, Esteban , Fonseca, Rafael

Mayo Clinic

Blood | February 20, 2013 | Volume: 121 | Issue: 16 | Pages: 3147-3152

10.1182/blood-2012-07-443606 | PMID 23422747 Get It

Key PointsIn this study, African American MM patients have a significantly lower frequency of IgH translocations than European American patients.
Lipomas of the cerebellopontine angle and internal auditory canal
White, James R. , Carlson, Matthew L. , Neff, Brian A., Driscoll, Colin L. W., Lane, John I. , Link, Michael J., Gompel, Jamie J. Van

Mayo Clinic

The Laryngoscope | February 10, 2013 | Volume: 123 | Issue: 6 | Pages: 1531-1536

10.1002/lary.23882 | PMID 23401141 Get It

Objectives/HypothesisTo describe the presentation and clinical course of cerebellopontine angle (CPA) and internal auditory canal (IAC) lipomas.Study DesignRetrospective cohort study at a tertiary academic referral center.MethodsAll patients presenting with a CPA or IAC mass radiographically consistent with a lipoma on high‐resolution magnetic resonance imaging (MRI) were identified. Data including presenting symptomatology, tumor characteristics, management strategy, and patient course were collected.ResultsBetween 1996 and 2012, 15 patients were diagnosed with a CPA or IAC lipoma at the authors' institution and were included in the analysis. The mean duration of radiological and clinical follow‐up was 3.4 years and 5.1 years, respectively. Eight lesions were confined to the IAC, while seven involved the CPA. The median tumor size at diagnosis was 7.2 mm; one patient demonstrated tumor growth on serial MRI while the remaining subjects did not have radiological progression. The most common presenting symptoms were sensorineural hearing loss (40%) and tinnitus (33%); five patients were diagnosed after incidental discovery on MRI. Fourteen patients were managed with observation, while one subject underwent subtotal resection. None of the observed patients reported worsening symptoms at last follow‐up.ConclusionsWhile rare, lipomas should be included in the differential diagnosis of CPA and IAC lesions. Owing to a generally benign clinical course and high morbidity associated with resection, microsurgery should only be considered in cases of definite tumor enlargement with intractable symptoms from mass effect. Careful radiological evaluation is critical for establishing an accurate diagnosis in order to prevent unnecessary morbidity associated with resection.Level of Evidence2b.
Brain carcinoid metastases: outcomes and prognostic factors
Mallory, Grant W., Fang, Shanna, Parney, Ian F. , Giannini, Caterina , Gompel, Jamie J. Van , Parney, Ian F

Mayo Clinic

Journal of Neurosurgery | February 8, 2013 | Volume: 118 | Issue: 4 | Pages: 889-895

10.3171/2013.1.jns121556 | PMID 23394337 Get It

Object Carcinoid tumors are rare and have generally been regarded as indolent neoplasms. Systemic disease is often incurable; however, patients may live years with this disease. Furthermore, metastatic brain lesions are extremely uncommon. As such, few series have examined outcomes and prognostic factors in those with brain involvement. Methods The authors performed a retrospective review of patients who underwent primary treatment at Mayo Clinic in Rochester, Minnesota, for metastatic carcinoid tumors to the brain between 1986 and 2011. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier statistics. Cox proportional hazards were used to determine predictors of survival. Results Fifteen patients underwent primary treatment for metastatic carcinoid tumors to the brain between 1986 and 2011. Their mean age was 58 ± 12 years. Eighty percent (n = 12) of patients underwent surgery, whereas 2 received stereotactic radiosurgery and 1 had whole-brain radiation therapy (WBRT) as the primary treatment. The median follow-up duration was 19 months (maximum 124 months). Systemic disease progression occurred in 73% and was the leading cause of death in known cases, while intracranial disease recurred in 40%. The median PFS and OS were 21 and 19 months, respectively. The use of adjuvant WBRT correlated with improved PFS (HR 0.15, CI 0.0074–0.95, p = 0.044). Those who underwent surgery as primary modalities trended toward longer progression-free intervals (p = 0.095), although this did not reach significance. Conclusions Metastatic carcinoid disease to the brain appears to have a worse prognosis than that of other extracranial metastases. Although there was a trend toward a survival advantage in patients who underwent surgery and WBRT, further study is needed to establish definitive treatment recommendations.
Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience
Azambuja, Evandro de , Bradbury, Ian , Saini, Kamal S. , Simon, Sérgio D. , Dooren, Veerle Van, Aktan, Gursel, Wolff, Antonio C. , Jackisch, Christian , Láng, István, Boyle, Frances , Baselga, José , Perez, Edith A. , Piccart, Martine , Metzger, Otto , Bines, José , Pritchard, Kathleen I. , Smith, Ian , Untch, Michael , Xu, Binghe , Wolff, Antonio C , de Azambuja, Evandro

Mayo Clinic

The Oncologist | January 29, 2013 | Volume: 18 | Issue: 2 | Pages: 134-140

10.1634/theoncologist.2012-0342 | PMID 23359433 Get It

Abstract Learning Objectives Discuss methods for improving the efficiency of global clinical trials. Explain the need for national regulatory authorities and collaborative cancer groups to initiate efforts to quicken the activation process in their countries. Describe the activation process of phase III studies and its complex and heterogeneous regulation across different geographic and economic regions. Purpose. This study measured the time taken for setting up the different facets of Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO), an international phase III study being conducted in 44 participating countries. Methods. Time to regulatory authority (RA) approval, time to ethics committee/institutional review board (EC/IRB) approval, time from study approval by EC/IRB to first randomized patient, and time from first to last randomized patient were prospectively collected in the ALTTO study. Analyses were conducted by grouping countries into either geographic regions or economic classes as per the World Bank's criteria. Results. South America had a significantly longer time to RA approval (median: 236 days, range: 21–257 days) than Europe (median: 52 days, range: 0–151 days), North America (median: 26 days, range: 22–30 days), and Asia-Pacific (median: 62 days, range: 37–75 days). Upper-middle economies had longer times to RA approval (median: 123 days, range: 21–257 days) than high-income (median: 47 days, range: 0–112 days) and lower-middle income economies (median: 57 days, range: 37–62 days). No significant difference was observed for time to EC/IRB approval across the studied regions (median: 59 days, range 0–174 days). Overall, the median time from EC/IRB approval to first recruited patient was 169 days (range: 26–412 days). Conclusion. This study highlights the long time intervals required to activate a global phase III trial. Collaborative research groups, pharmaceutical industry sponsors, and regulatory authorities should analyze the current system and enter into dialogue for optimizing local policies. This would enable faster access of patients to innovative therapies and enhance the efficiency of clinical research.
Symptomatic internal carotid artery medialization: A rare anatomic variant resulting in cough, dysphonia, and dysphagia
Abel, Kathryn M. Van , Carlson, Matthew L. , Moore, Eric J. , Van Abel, Kathryn M

Mayo Clinic

Clinical Anatomy | January 28, 2013 | Volume: 26 | Issue: 8 | Pages: 966-970

10.1002/ca.22178 | PMID 23355276 Get It

Primary inner ear schwannomas: A case series and systematic review of the literature
Abel, Kathryn M. Van , Carlson, Matthew L. , Link, Michael J. , Neff, Brian A., Beatty, Charles W., Lohse, Christine M. , Eckel, Laurence J. , Lane, John I. , Driscoll, Colin L. W., Van Abel, Kathryn M

Mayo Clinic

The Laryngoscope | January 18, 2013 | Volume: 123 | Issue: 8 | Pages: 1957-1966

10.1002/lary.23928 | PMID 23335152 Get It

Objectives/HypothesisTo describe the natural history of primary inner ear schwannomas (PIES) and evaluate management outcomes and relationship between PIES location, clinical presentation, and time to diagnosis.Study DesignRetrospective chart review and systematic review of the literature.MethodsVestibular schwannoma confined to or arising from the inner ear were included. PIES classification was based on anatomic subsite(s) involved. Detailed clinical history and outcomes were recorded.ResultsIn a systematic review (1933–2011), including 14 patients from the authors' institution (1999–2009), a total of 72 studies comprising 234 patients were evaluated. Mean follow‐up was 32.8 ± 39.1 months (range, 0–183 months). The cochlea was the most commonly involved subsite (51%). Hearing loss was the most frequent presenting symptom (99%). Vertigo and abnormal balance were more common among tumors involving the vestibular system (P < .01). Average delay between symptom onset and diagnosis was 7.0 ± 8.0 years (median, 5 years; range, 0–40 years). Recent onset hearing loss was more likely to elicit an earlier diagnosis (P = .01). The majority of patients were observed without treatment (53%). Tumor progression was seen in 52% of patients.Conclusions PIES are rare tumors and most commonly involve the cochlea. Tumor location is often associated with clinical presentation and correlates with delay between symptom onset and diagnosis. A watch‐and‐scan approach is the management strategy of choice in the absence of intractable vertigo or extensive tumor growth. The majority of patients report stable or improved symptoms over time, regardless of treatment. Laryngoscope, 123:1957–1966, 2013
RTOG 9802: Good Wines Need Aging
Bent, Martin J. van den , Jaeckle, Kurt A. , Baumert, Brigitta G. , Wick, Wolfgang , van den Bent, Martin J

Mayo Clinic

Journal of Clinical Oncology | January 8, 2013 | Volume: 31 | Issue: 5 | Pages: 653-654

10.1200/jco.2012.46.6896 | PMID 23295798 Get It

Shining a light on posterior cortical atrophy
Crutch, Sebastian J. , Schott, Jonathan M. , Rabinovici, Gil D. , Cappa, Stefano F. , Dubois, Bruno , Graff‐Radford, Neill R., Krolak‐Salmon, Pierre , Lehmann, Manja , Mendez, Mario F. , Pijnenburg, Yolande A.L. , Ryan, Natalie S. , Scheltens, Philip , Shakespeare, Timothy J. , Tang‐Wai, David F. , Flier, Wiesje M. van der , Bain, Lisa J. , Carrillo, María C. , Fox, Nick C. , Boeve, Bradley F. , Dickerson, Bradford Clark , Graff‐Radford, Neill R., van der Flier, Wiesje M , Scheltens, Philip , Fox, Nick C , Rabinovici, Gil D , Schott, Jonathan M , Pijnenburg, Yolande A L

Mayo Clinic

Alzheimer's & Dementia | December 28, 2012 | Volume: 9 | Issue: 4 | Pages: 463-465

10.1016/j.jalz.2012.11.004 | PMID 23274153 Get It

Abstract Posterior cortical atrophy (PCA) is a clinicoradiologic syndrome characterized by progressive decline in visual processing skills, relatively intact memory and language in the early stages, and atrophy of posterior brain regions. Misdiagnosis of PCA is common, owing not only to its relative rarity and unusual and variable presentation, but also because patients frequently first seek the opinion of an ophthalmologist, who may note normal eye examinations by their usual tests but may not appreciate cortical brain dysfunction. Seeking to raise awareness of the disease, stimulate research, and promote collaboration, a multidisciplinary group of PCA research clinicians formed an international working party, which had its first face‐to‐face meeting on July 13, 2012 in Vancouver, Canada, prior to the Alzheimer's Association International Conference.
Bub1 kinase activity drives error correction and mitotic checkpoint control but not tumor suppression
Ricke, Robin M., Jeganathan, Karthik B. , Malureanu, Liviu, Harrison, Andrew M. , Deursen, Jan M. van , Harrison, Andrew Marc , Jeganathan, Karthik B

Mayo Clinic

Journal of Cell Biology | December 4, 2012 | Volume: 199 | Issue: 6 | Pages: 931-949

10.1083/jcb.201205115 | PMID 23209306 Get It

The mitotic checkpoint protein Bub1 is essential for embryogenesis and survival of proliferating cells, and bidirectional deviations from its normal level of expression cause chromosome missegregation, aneuploidy, and cancer predisposition in mice. To provide insight into the physiological significance of this critical mitotic regulator at a modular level, we generated Bub1 mutant mice that lack kinase activity using a knockin gene-targeting approach that preserves normal protein abundance. In this paper, we uncover that Bub1 kinase activity integrates attachment error correction and mitotic checkpoint signaling by controlling the localization and activity of Aurora B kinase through phosphorylation of histone H2A at threonine 121. Strikingly, despite substantial chromosome segregation errors and aneuploidization, mice deficient for Bub1 kinase activity do not exhibit increased susceptibility to spontaneous or carcinogen-induced tumorigenesis. These findings provide a unique example of a modular mitotic activity orchestrating two distinct networks that safeguard against whole chromosome instability and reveal the differential importance of distinct aneuploidy-causing Bub1 defects in tumor suppression.
Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration
Loeb, Stacy , Sokoll, Lori J. , Broyles, Dennis L., Bangma, Chris H. , Schaik, Ron H. N. van , Klee, George G., Wei, John T., Sanda, Martin G. , Partin, Alan W. , Slawin, Kevin M., Marks, Leonard S. , Mizrahi, Isaac, Shin, Sanghyuk S. , Cruz, Amabelle B., Chan, Daniel W. , Roberts, William L. , Catàlona, William J. , Loeb, Stacy

Mayo Clinic

Journal of Urology | November 30, 2012 | Volume: 189 | Issue: 5 | Pages: 1702-1706

10.1016/j.juro.2012.11.149 | PMID 23206426 Get It